Your application is in.
Book a quick call with the founder.

The Kannaco wholesale program is open to licensed healthcare practitioners including chiropractors, physical therapists, sports medicine physicians, integrative medicine practitioners, nurse practitioners, physician assistants, massage therapists, and other licensed clinical professionals. We verify licensure during the onboarding call. There is no minimum order requirement after the initial starter pack, and accounts can be opened the same day as the onboarding call.

Wholesale pricing is $32.50 per unit across all three formulas — Pro Cream, Cooling Cream, and Pro Roll-On. The suggested MSRP range is $64.50 to $84.99 per unit, depending on your practice positioning and patient population. At $64.50 MSRP your margin is approximately 49.6%. At $84.99 MSRP your margin is approximately 61.8%. Most practitioners price between $69.99 and $79.99. There are no required price floors — pricing is at your discretion.

The recommended starter order is 4 units of each formula — Pro Cream, Cooling Cream, and Pro Roll-On — for a total of 12 units at $390 wholesale. This gives you one of each formula to use in-office for patient trials, plus inventory to sell immediately. Most practitioners sell through their first order within 30 to 45 days. The three-formula starter ensures you can match the right product to each patient presentation rather than limiting yourself to a single formula.

Pro Cream (40mg/mL CBD+CBG, broad spectrum) is the most versatile formula — recommended for deep musculoskeletal discomfort, chronic presentations, and patients who prefer a warming sensory profile. Cooling Cream (25mg/mL, full spectrum) is recommended for acute flares, joint stiffness, and patients who prefer a cooling menthol sensation. Pro Roll-On (33mg/mL, CBD isolate, 0.0% THC) is recommended for drug-tested athletes, on-the-go application, and precision targeting of smaller joints. For most new patients, Pro Cream is the strongest starting point. For drug-tested athletes, Pro Roll-On is the only appropriate recommendation.

The most effective patient explanation focuses on the Endocannabinoid System (ECS) and the CB2 receptor distribution in peripheral tissue. The key points: the ECS is a natural regulatory system present in every human body; CB2 receptors are distributed throughout musculoskeletal tissue, joints, and skin; topical CBD interacts with these receptors locally without entering the bloodstream in meaningful amounts; and the effect is cumulative over 7 to 14 days of consistent twice-daily application. Kannaco provides a one-page patient education card with each wholesale order that covers these points in plain language.

For drug-tested athletes and patients in safety-sensitive occupations, the Pro Roll-On is the appropriate recommendation. It uses CBD Isolate — meaning it contains only CBD with no other cannabinoids, including THC. Every batch is tested by SC Labs (ISO/IEC 17025 accredited) and verified at 0.0% THC. Full spectrum and broad spectrum products carry a theoretical risk of trace THC accumulation with extended heavy use, even when THC is below the 0.3% federal limit. For any patient where a positive drug test would have professional consequences, isolate-only products are the conservative clinical recommendation.

Every Kannaco batch is tested by SC Labs, one of fewer than 5% of cannabis testing laboratories in the United States to hold ISO/IEC 17025 accreditation — the same international standard used by pharmaceutical testing laboratories. The full panel includes cannabinoid potency (12+ cannabinoids), heavy metals (lead, arsenic, cadmium, mercury), pesticide residue (66-compound panel), microbial contamination (total yeast/mold, E. coli, Salmonella), and residual solvents. COAs are publicly accessible on the Kannaco website and searchable by batch number printed on each product label. Kannaco is also LegitScript certified and manufactured in a GMP-compliant U.S. facility.

Topical CBD has a fundamentally different safety profile than oral CBD because it does not enter systemic circulation in meaningful amounts. The primary drug interaction concern with oral CBD — inhibition of CYP450 enzymes (particularly CYP3A4 and CYP2C9), which can affect the metabolism of anticoagulants, immunosuppressants, and certain antiepileptics — is not a clinically significant concern with topical application at standard doses. For patients on anticoagulants, we recommend a conservative approach: advise them to mention the topical CBD to their prescribing physician and monitor as you would with any new topical product. For patients with no systemic medication concerns, topical CBD at standard doses has no established clinically significant drug interactions.

Every wholesale order includes patient education cards (one per unit) that explain the ECS, topical mechanism, and application protocol in plain language suitable for patient distribution. Practitioners also receive access to the Kannaco practitioner portal, which includes digital patient education materials, clinical reference guides, formula selection guides, and printable protocol sheets. Social media assets and practice marketing materials are available on request. There is no additional charge for any of these materials — they are included as part of the wholesale program.

The 15-minute onboarding call covers your application review, practice fit assessment, wholesale terms, and starter order recommendation. If everything aligns — which it does for the vast majority of applicants — your wholesale account is opened on the call and you can place your first order immediately after. Orders ship within 1 to 2 business days from our U.S. facility. Most practitioners receive their first order within 3 to 5 business days of the call. There is no waiting period, no approval delay, and no minimum order commitment beyond the initial starter pack.